Bacil Pharma share news, announcements and annual reports
BSE: 524516Pharmaceuticals & BiotechnologySmall Cap
Bacil Pharma Ltd. · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 1994
Last close ₹18.81up ₹0.41 (2.23%)
Share price at the BSE close on 30 Oct 2026. Previous close ₹18.40.
30 Oct: open ₹18.50, high ₹18.99, low ₹18.40
52-week range of traded prices to 30 Oct 2026
₹10.65Low, 26 Aug 2026₹61.80High, 10 Apr 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹27 Cr3,172nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Taken from the consolidated balance sheet, the company and its subsidiaries together; the P/E is on the company's own results until four consolidated quarters are filed. Price to book: how it is worked out
- 1.07
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −0.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026. Taken from the consolidated balance sheet, the company and its subsidiaries together; the P/E is on the company's own results until four consolidated quarters are filed.
- 0.00
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 1,126
Bacil Pharma share news and announcements
542 announcements, routine notices left out, newest first. Page 6 of 11.
May 2022
23 May · Board meeting
Meeting on 30 May 2022: audited results and quarterly results13 May · Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
Apr 2022
Feb 2022
14 Feb · Results
14 Feb · Board meeting
4 Feb · Board meeting
Meeting on 14 Feb 2022: quarterly results
Jan 2022
20 Jan · Shareholding for the Period Ended December 31, 2021
Shareholding Pattern for the Period Ended December 31, 2021. For more details, kindly Click ....19 Jan · Statement Of Investor Complaints For The Quarter Ended December 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0
Nov 2021
12 Nov · Results
12 Nov · Board meeting
2 Nov · Board meeting
Meeting on 12 Nov 2021: quarterly results
Oct 2021
21 Oct · Shareholding for the Period Ended September 30, 2021
Shareholding Pattern for the Period Ended September 30, 2021. For more details, kindly Click ....14 Oct · Statement Of Investor Complaints For The Quarter Ended September 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0
Sep 2021
28 Sep · Results
Details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly ....
Aug 2021
31 Aug · Meeting
31 Aug · Meeting
6 Aug · Board meeting
Meeting on 14 Aug 2021: quarterly results
Jul 2021
19 Jul · Shareholding for the Period Ended June 30, 2021
Shareholding Pattern for the Period Ended June 30, 2021. For more details, kindly Click ....19 Jul · Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0
Jun 2021
23 Jun · Board meeting
Meeting on 30 Jun 2021: audited results and quarterly results
Apr 2021
21 Apr · Compliance Certificate For The Half Year Ended 31.03.2021
17 Apr · Shareholding for the Period Ended March 31, 2021
Shareholding Pattern for the Period Ended March 31, 2021. For more details, kindly Click ....17 Apr · Statement Of Investor Complaints For The Quarter Ended March 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0
Mar 2021